Study Protocol of a Prospective Multicenter Study on Patient Participation for the Clinical Trial: Surgery as Needed Versus Surgery on Principle in Post-Neoadjuvant Complete Tumor Response of Esophageal Cancer (ESORES).
esophageal cancer (EC)
informed consent
patient participation
patient-centered
psycho-social needs
study information
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
10
2021
accepted:
24
12
2021
entrez:
4
2
2022
pubmed:
5
2
2022
medline:
5
2
2022
Statut:
epublish
Résumé
Ideally, patient-centered trial information material encourages the discussion with the treating physician, and helps patients making trade-offs regarding treatment decisions In a situation of possible equivalent treatment options in terms of overall survival (OS), it can make it easier to weigh up advantages and disadvantages. Preferences for choice of treatment in esophageal cancer (EC) are complex, and no standardized assessment tools are available. We will explore patient's factors for treatment choice and develop a comprehensive patient information leaflet for the inclusion into randomized controlled trials (RCT) on EC. We conduct a cross-sectional, observational study based on a mixed-methods design with patients suffering from non-metastatic EC with post-neoadjuvant complete response after neoadjuvant chemotherapy (nCT) or neoadjuvant chemoradiation (nCRT), to develop patient-centered trial information material. This pilot study is performed in a concept development phase and a subsequent pilot phase. We start with patient interviews (
Identifiants
pubmed: 35117993
doi: 10.3389/fonc.2021.789155
pmc: PMC8803636
doi:
Types de publication
Journal Article
Langues
eng
Pagination
789155Informations de copyright
Copyright © 2022 Weis, Kiemen, Schmoor, Hipp, Czornik, Reeh, Grimminger, Bruns and Hoeppner.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Oncol. 2007 Apr 1;25(10):1160-8
pubmed: 17401004
Br J Surg. 2011 Aug;98(8):1124-31; discussion 1132
pubmed: 21674471
Ann Fam Med. 2011 Mar-Apr;9(2):100-3
pubmed: 21403134
BMC Cancer. 2018 Feb 6;18(1):142
pubmed: 29409469
World J Surg. 2015 Oct;39(10):2492-9
pubmed: 26170156
Clin Gastroenterol Hepatol. 2015 Jan;13(1):91-3
pubmed: 24823291
Eur J Cancer. 1998 Sep;34(10):1554-9
pubmed: 9893627
BMJ Qual Saf. 2018 May;27(5):380-388
pubmed: 29269567
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Cancer. 2014 Feb 15;120(4):492-8
pubmed: 24194477
Cancers (Basel). 2019 Feb 05;11(2):
pubmed: 30764578
BMJ Open. 2016 Feb 02;6(2):e010008
pubmed: 26839014
BMJ. 2002 Apr 6;324(7341):827-30
pubmed: 11934777
Eur J Cancer. 2003 Jul;39(10):1384-94
pubmed: 12826041
Br J Cancer. 2002 Oct 7;87(8):854-8
pubmed: 12373599
Anticancer Res. 2019 Sep;39(9):5123-5133
pubmed: 31519624
Dis Esophagus. 2017 Oct 1;30(10):1-7
pubmed: 28859397
Br J Surg. 2008 Sep;95(9):1121-6
pubmed: 18581441
J Clin Oncol. 2010 Feb 10;28(5):738-43
pubmed: 20065187
Cancers (Basel). 2021 Jan 23;13(3):
pubmed: 33561090
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
J Gen Intern Med. 2012 Oct;27(10):1361-7
pubmed: 22618581
Br J Cancer. 2002 Mar 18;86(6):851-7
pubmed: 11953814
J Psychosom Res. 2005 Jun;58(6):505-11
pubmed: 16125517
Ann Surg Oncol. 2019 Dec;26(13):4765-4772
pubmed: 31620943
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
Lancet Oncol. 2016 Dec;17(12):1697-1708
pubmed: 27776843
Oncology. 2013;85(2):95-9
pubmed: 23860252
Oncology. 2012;83(5):300-4
pubmed: 22964903
Lancet Oncol. 2015 Sep;16(9):1090-1098
pubmed: 26254683
Patient Educ Couns. 2013 Feb;90(2):207-12
pubmed: 22854227
Br J Surg. 2018 Nov;105(12):1630-1638
pubmed: 29947418
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941